Dr. Cristiano Ferrario
Dr. Ferrario received his MD degree in 2001 and his Specialty Certificate in Medical Oncology in 2005, both from the University of Milan in Italy. After training in Milan (Istituto Nazionale Tumori), Dr Ferrario moved to Montreal (Canada) to work in basic research at the Lady Davis Institute for two years. In 2007 he was awarded the Terry Fox Foundation Post MD Research Fellowship Award and then started on a clinical fellowship program for four years in the Oncology Department of McGill University, training in clinical research in breast cancer, hepatobiliary and prostate cancers. In 2011 he moved back to Italy, where he worked for two years as a medical oncologist at the “IRST” (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) in Meldola, focusing on breast cancer and on the treatment of refractory testicular cancer with high-dose chemotherapy. In 2012 he accepted a position as Assistant Professor in the Oncology Department of McGill University (Montreal) and Medical Oncologist at the Segal Cancer Centre (Jewish General Hospital, Montreal), where he is currently working. In 2012 he was the recipient of the Kate McGarrigle Fellowship Award.
Dr. Ferrario is very involved in the training of McGill Medical Oncology Residents, and he is the Lead of the Competence Committee of the Residency program. In his busy clinics, Dr. Ferrario treats several patients with prostate, bladder, and breast cancers at the Segal Cancer Centre and is particularly dedicated to clinical research. He is the local responsible for more than 20 phase 1-3 clinical trials, offering innovative treatments to patients with advanced cancers. Many of these trials include new immunotherapy strategies and genomics-driven personalized therapies, also integrating ct-NDA screening.
As the local PI for the CCTG study Captur, Dr. Ferrario started the first Molecular Tumor Board in Quebec, which he has been co-leading in biweekly meetings since September 2018.